Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Free Cash Flow (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Free Cash Flow for 7 consecutive years, with $126.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 67.95% to $126.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $347.9 million through Dec 2025, up 59.09% year-over-year, with the annual reading at $347.9 million for FY2025, 59.09% up from the prior year.
  • Free Cash Flow hit $126.0 million in Q4 2025 for Harmony Biosciences Holdings, up from $108.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $126.0 million in Q4 2025 to a low of $12.5 million in Q1 2021.
  • Historically, Free Cash Flow has averaged $51.4 million across 5 years, with a median of $39.8 million in 2021.
  • Biggest five-year swings in Free Cash Flow: surged 273.57% in 2021 and later fell 28.92% in 2022.
  • Year by year, Free Cash Flow stood at $37.5 million in 2021, then dropped by 28.92% to $26.7 million in 2022, then soared by 186.97% to $76.6 million in 2023, then decreased by 1.97% to $75.0 million in 2024, then surged by 67.95% to $126.0 million in 2025.
  • Business Quant data shows Free Cash Flow for HRMY at $126.0 million in Q4 2025, $108.7 million in Q3 2025, and $79.3 million in Q2 2025.